A Study to Assess the Safety and Pharmacokinetics of Subcutaneously Administered Golimumab, a Human Anti-TNFα Antibody, in Pediatric Patients With Moderate to Severe Active Ulcerative Colitis
- First Posted Date
- 2013-07-16
- Last Posted Date
- 2023-05-11
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 35
- Registration Number
- NCT01900574
A Study to Assess the Relative Bioavailability of 4 New Abiraterone Acetate Tablet Formulations With Respect to the Current Commercial Abiraterone Acetate Tablet Under Fasted Conditions in Healthy Male Participants
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2013-07-12
- Last Posted Date
- 2014-12-02
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 32
- Registration Number
- NCT01897389
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-54861911 in Healthy Elderly Participants
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2013-06-27
- Last Posted Date
- 2014-01-14
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 70
- Registration Number
- NCT01887535
An Observational Study of Oral Fluoroquinolones and the Risk of Retinal Detachment
Completed
- Conditions
- Retinal Detachment
- First Posted Date
- 2013-06-19
- Last Posted Date
- 2013-06-19
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 119924
- Registration Number
- NCT01881438
A Study to Assess Different Diagnostic Criteria of Chronic Constipation in Asia
- First Posted Date
- 2013-06-18
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 461
- Registration Number
- NCT01880294
A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure
Phase 3
Completed
- Conditions
- Coronary Artery DiseaseHeart Failure
- Interventions
- First Posted Date
- 2013-06-14
- Last Posted Date
- 2019-05-10
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 5081
- Registration Number
- NCT01877915
A Study to Assess the Effect of Abiraterone (JNJ-589485) on the Pharmacokinetics of Pioglitazone Following Administration of Abiraterone Acetate (JNJ-212082) and Pioglitazone HCl Tablets in Healthy Male Participants
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2013-06-07
- Last Posted Date
- 2014-04-17
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 16
- Registration Number
- NCT01873001
An Effectiveness and Safety Study of Inhaled JNJ 49095397 (RV568) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
Phase 2
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2013-06-04
- Last Posted Date
- 2019-08-21
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 211
- Registration Number
- NCT01867762
A Study to Assess the Absolute Bioavailability of Oral PCI-32765 and the Effect of Grapefruit Juice on the Bioavailability of PCI-32765 in Healthy Participants
Phase 1
Completed
- Conditions
- Healthy Volunteer
- Interventions
- Drug: PCI-32765 (Treatment A)Drug: PCI-32765 (Treatment B)Drug: PCI-32765 (Treatment C)Drug: 13C6 PCI-32765 (reference)
- First Posted Date
- 2013-05-31
- Last Posted Date
- 2014-03-18
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 8
- Registration Number
- NCT01866033
A Study to Assess the Pharmacokinetic Comparability of Guselkumab (CNTO1959) When Delivered by 2 Different Devices and as 2 Formulations in Healthy Participants
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2013-05-31
- Last Posted Date
- 2020-01-27
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 141
- Registration Number
- NCT01866007
© Copyright 2025. All Rights Reserved by MedPath